logo
Argentines reel from health care cutbacks as President Milei's state overhaul mirrors Trump's

Argentines reel from health care cutbacks as President Milei's state overhaul mirrors Trump's

BUENOS AIRES, Argentina (AP) — To outsiders, the Facebook group chat reads like a snarl of nonsensical emojis and letters. To uninsured Argentine cancer patients, it's a lifeline.
The surreptitious network connects advocates who have spare drugs to Argentines with cancer who lost access to their treatment in March 2024 when
President Javier Milei
suspended a federal agency, known as DADSE, that paid for their expensive medications.
Whenever Facebook cracks the coded pleas and removes the group for violating its rules on drug sales, another appears, swelling with Argentines who say they've grown sicker since the radical libertarian president
took a chainsaw
to health care.
'All I need for my body to function is this medication, and Milei is saying, 'There's no money,'' said Ariel Wagener, a 47-year-old pizza chef with leukemia who was hospitalized this year with failing kidneys after losing access to his medication. Without DADSE, a month's worth of his leukemia drug costs $21,000.
Wagener's condition stabilized after he got leftover medication via Facebook, donated by a family whose loved one had died of cancer.
The halting of millions of dollars of free cancer drugs is just one way
Milei's austerity drive
has torn through the public health system that once set Argentina apart in Latin America, ensuring that health care was free for pretty much everyone who couldn't afford private insurance.
Since
taking office in December 2023
, Milei has slashed Argentina's health care budget by 48% in real terms. His administration fired over 2,000 Health Ministry employees, including 1,400 over just a few days in January.
As part of Milei's plan to
remake Argentina's troubled economy
and cut waste and bureaucracy, officials gutted the National Cancer Institute, suspending early detection programs for breast and cervical cancer.
They froze federal funds for immunization campaigns, hobbling vaccine access as Argentina confronts a measles outbreak for the first time in decades. They dismantled the National Directorate for HIV, Hepatitis and Tuberculosis, leading to testing and treatment delays. They defunded emergency contraception and stopped distributing
abortion
pills.
'We're seeing setbacks we haven't seen in decades,' said María Fernanda Boriotti, president of Argentina's Federation of Health Professionals. 'HIV patients without treatment, cancer patients dying for lack of medication, hospitals without resources, health professionals pushed out of the system.'
The government curtailed medical coverage for retirees and lifted price controls on prescription medication and private health plans, causing prices to spike by 250% and 118% respectively, official data shows.
'We've stopped buying milk, yogurt, anything that's not absolutely essential,' said Susana Pecora, 71, who lost the insurance plan that covered her husband's antipsychotic drugs when the price jumped 40% last year.
Milei and Trump see eye-to-eye
Milei campaigned on a promise to shrink the state two years before
President Donald Trump
and
Elon Musk
took up
their own chainsaws
.
The Argentine has become a close ally of the Trump administration, including on health policy.
Argentina has
followed the
U.S. out of the World Health Organization
, and last month received a visit from U.S. Secretary of Health and Human Services
Robert F. Kennedy Jr
.
Meeting Kennedy in Buenos Aires, Argentine Health Minister Mario Lugones announced a review of Argentina's health system to align it with Kennedy's
Make America Healthy Again
movement.
'We have similar visions about the path forward,' Lugones said of Kennedy.
Milei has not yet attempted to replace universal coverage with an insurance-based system, as he vowed on the campaign trail.
But in stripping Argentines of coverage and increasing premiums and out-of-pocket expenses, he is moving Argentina closer to the U.S. model, said Macarena Sabin Paz, health team coordinator at Argentina's Center for Legal and Social Studies.
'We are beginning to see the idea ... where if you lose your job, or become seriously ill, you may have to sell your car, whatever you have, to pay for health care,' she said.
Milei's staffing cuts have eviscerated agencies tasked with planning, financing and tracking immunization campaigns, disrupting data collection and jeopardizing the country's respected childhood vaccine program.
The cuts have coincided with a measles outbreak that in April led to Argentina's first measles death in two decades.
'Argentina has been one of the most advanced South American countries and here we see it abandoning public health,' said Dr. Stanley Plotkin, an American physician who helped develop the measles vaccine in the 1960s.
Milei's spokesperson, Manuel Adorni, did not respond to requests for comment. Lugones also did not respond to questions on the impact of policy changes.
A tidal wave of cuts
After decades of unbridled spending by left-wing populist governments that brought Argentina
infamy for defaulting on its debts
, Milei delivered on his campaign promises of
taming extreme inflation
and notching a fiscal surplus.
But even experts who agree Argentina's health care system needed reform say the cutbacks have been so deep and fast that they've hit like a tidal wave.
'In terms of the destruction of the state, we've never experienced anything like this, not even during the military dictatorship,' said Fabio Nuñez, ex-coordinator of the National Directorate for HIV, Hepatitis and Tuberculosis who was among hundreds fired from the agency.
Charged with leading prevention efforts and treatments for infectious diseases, the agency has lost 40% of its staff and 76% of its annual budget. Hospitals now face shortages of everything from virus testing supplies to medications to condoms.
The cuts have coincided with a surge in sexually transmitted infections. Last year HIV cases spiked by 20% and syphilis by 50%.
'They're avoiding the expense now but will pay for it later as people seek emergency care,' said Cristian Pizzuti, a 31-year-old with HIV who documented 103 cases of patients deprived of their daily antiretroviral pills for weeks at a time last year. Pizzuti said he recently received expired medication and suffered a severe allergic reaction after being switched to a cheaper drug.
Tuberculosis cases also climbed by 25% last year. TB clinics report delays in obtaining test results.
'As people go about their lives, waiting for results, they are spreading the disease to others,' said Dr. Santiago Jimenez, who treats HIV and TB patients in an impoverished Buenos Aires neighborhood. 'It's an epidemiological disaster.'
Hospitals under strain
Free public hospitals have become flooded with Argentines who dropped their private insurance due to increased premiums or who lost their job — and with it, their social security plans funded through payroll contributions. Buenos Aires facilities reported a 20%-30% increase in demand in the first quarter of 2025 compared to the same period last year.
The strain was visible at the free public Rodolfo Rossi Hospital in La Plata last month, where crowds jostled in the outpatient clinic and long lines spilled from the pharmacy.
Pharmacists have reported drug shortages as mass layoffs caused administrative chaos and the government froze a program that provided basic medications to Argentine public health centers.
Silvana Mansilla, 43, spent half the day waiting to pick up her monthly supply of thyroid medication — which has doubled in price to $22 — only to find the hospital had run out. 'Where's the government? What are they doing about this?' she asked.
With hiring frozen, doctors said they're handling double the patient load.
Overwhelmed by ever-increasing workloads, Argentina's leading public Garrahan Pediatric Hospital in Buenos Aires has hemorrhaged 200 medical professionals since Milei took office.
As
annual inflation neared 200% last fall
, their salaries lost half of their purchasing power. Doctors left for jobs abroad or better-paying work in private clinics. None were replaced. Medical residents ran a weeklong strike in May, displaying their pay slips for a month of 70-hour work weeks: $700.
Waiting for treatment
A lawsuit filed by patient advocacy groups said more than 60 cancer patients have died due to the government's suspension of the DADSE medication program, and over 1,500 patients were waiting for their drugs.
A federal judge ordered the government to reinstate the drug deliveries, but it appealed, arguing that DADSE no longer exists. It said it had created a new, more efficient program to fulfill outstanding requests. But the timeline varies and sometimes the drugs don't come at all.
Timing was everything for patients like Alexis Almirón.
His medical records show the government drug bank received his request for an expensive medication to shrink his malignant tumor on Dec. 11, 2023, the day after Milei's inauguration. His doctor told the agency immediate treatment was urgently needed for the aggressive cancer.
Months passed. His mother, Claudia Caballero, bombarded DADSE with desperate calls asking what was taking so long as Almirón's lymphoma spread from his neck to his brain and stomach. He vomited blood. He lost his eyesight. Caballero tried to crowd-source the $20,000 for a month's supply of the drug but couldn't raise enough.
On March 12 last year, Almirón died at 22.
'They didn't give him the chance to choose to live,' Caballero said, her voice breaking.
The day after she buried her son, Caballero received a call from the Health Ministry. They had good news, the caller said: Her son's medication had finally arrived.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

This company's drug could effectively end the HIV epidemic—but patients remember how it slow walked a past treatment
This company's drug could effectively end the HIV epidemic—but patients remember how it slow walked a past treatment

Fast Company

time41 minutes ago

  • Fast Company

This company's drug could effectively end the HIV epidemic—but patients remember how it slow walked a past treatment

Four decades after the human immunodeficiency virus was first identified, the end of the epidemic could be in sight. Thanks to treatments and preventive medications, new infections worldwide have fallen dramatically, from 3.3 million at their peak in 1995 to 1.3 million in 2023. Now, with the arrival of a groundbreaking drug from Gilead Sciences, there's serious talk about bringing new cases down to zero. Foster City, California–based Gilead is already the leader in HIV prevention. Its daily oral pill Descovy accounts for about 40% of the U.S. market for pre-exposure drugs, known as PrEP (pre-exposure prophylaxis). Sales of the company's portfolio of drugs for HIV prevention and treatment reached $19.6 billion in 2024. Some 75% of the nearly 40 million people worldwide who live with HIV receive a Gilead-branded drug or a generic version, according to the company. But the twice-a-year injectable lenacapavir, which is on track for a June 19 approval as PrEP by the U.S. Food and Drug Administration, has the potential to be a game changer. The first study of lenacapavir to prevent HIV infections, which included more than 5,000 women, showed it to be 100% effective—the first Phase 3 HIV-prevention trial ever with zero infections. In a subsequent study of more than 3,000 men, transgender people, and nonbinary individuals who had sex with male partners, lenacapavir reduced new HIV infections by 96% compared to background incidence. 'A twice-yearly injection to prevent the infection could change everything,' says Gilead CEO Daniel O'Day, 'putting an end to the epidemic and all the health and economic challenges that come with it.' According to one estimate, lenacapavir could avert up to a third of HIV infections in eastern and southern Africa over 10 years, if priced affordably enough. Gilead has trumpeted plans for the rollout of lenacapavir in low- and middle-income countries.

Thai Research Breakthrough Published in International Scientific Journal A Milestone of Success
Thai Research Breakthrough Published in International Scientific Journal A Milestone of Success

Yahoo

timean hour ago

  • Yahoo

Thai Research Breakthrough Published in International Scientific Journal A Milestone of Success

Thailand's National Innovation-Mangosteen-Based Immunotherapy Fights HIV/AIDS Bangkok, Thailand--(Newsfile Corp. - June 18, 2025) - The Operation BIM research team from Asian Phytoceuticals Public Company Limited, led by Professor Dr. Pichaet Wiriyachitra, has announced a significant achievement in immunotherapy innovation using Fortified Mangosteen Extracts. This natural formulation has helped 80 individuals living with HIV/AIDS reach a state known as "ByeByeHIV", characterized by strong health and, in some cases, the complete eradication of the virus from their bodies. The study has been published in the international journal Clinical Immunology Research under the title "ByeByeHIV with Thai Innovation." Thai Research Breakthrough Published in International Scientific Journal A Milestone of Success To view an enhanced version of this graphic, please visit: According to the Ministry of Public Health, in 2025, Thailand is projected to have 8,862 new HIV cases, 10,217 people have died from AIDS-related conditions, while 568,565 individuals are living with HIV. "ByeByeHIV" refers to a condition where HIV/AIDS patients can reduce their viral load to undetectable levels without the use of antiretroviral drugs (ARVs) while maintaining good health. It also applies to those who had adverse side effects from ARVs and can now discontinue treatment while staying healthy and HIV-undetectable. The ByeByeHIV innovation is based on a natural extract formula composed of mangosteen, black sesame, soy, guava, and Centella asiatica. This dietary supplement, approved by the Thai FDA, boosts immune functions—especially Th1, Th17, and Killer T cells—targeting infected cells and repairing HIV- and ARV-induced telomere damage. Based on the February 2024 publication titled "ByeByeHIV with Thai Innovation", (ByeByeHIV with Thai Innovation: the formula successfully helped two groups: Group A: 24 HIV-positive individuals never on ARVs Group B: 26 individuals previously treated with ARVs By December 2024, both groups expanded to 40 participants each, all of whom achieved ByeByeHIV. The latest journal article, ByeByeHIV with Plant-Based Immunotherapy: Progress Update on 40 Cases without the Use of ARV Drugs (Group A), reports all 40 participants in Group A achieved ByeByeHIV. Notably, 15 individuals stopped the mangosteen-based regimen for 6 months to over 4 years while maintaining undetectable viral loads and excellent health. The first participant to discontinue the formula has now been virus-free for nearly 10 years. This suggests complete HIV eradication for the 15 individuals. The Group B study (Progress Update on 40 Cases with Prior Use of ARV Drugs) shows that all 40 participants also reached ByeByeHIV, with 15 discontinuing the regimen for 3 months to over 2 years—remaining healthy and HIV-free. This implies HIV/AIDS may now be curable without relapse. ByeByeHIV with Plant-Based Immunotherapy: Progress Update on 40 Cases without the Use of ARV Drugs (Group A) ByeByeHIV with Plant-Based Immunotherapy: Progress Update on 40 Cases with Prior Use of ARV Drugs (Group B) These three remarkable recoveries highlight the potential of natural extract-based innovations in HIV treatment—restoring life quality to normalcy. All three individuals have publicly come forward and now serve as mentors, inspiring others to overcome stigma and reclaim their lives. Professor Dr. Pichaet summarized, "This study confirms the potential of ByeByeHIV formula as a viable alternative for HIV patients unable to tolerate ARVs or new patients avoiding long-term ARV use. This marks a historic milestone for Thailand—challenging the 40-year belief that HIV/AIDS cannot be cured." "This Thai national innovation deserves global recognition for safely awakening the body natural healing power without side effects. Though categorized as a supplement, it has achieved what pharmaceuticals could not. Legal frameworks should evolve to reflect modern scientific breakthroughs." Contact Info:Name: APCO Bangkok OfficeEmail: apco@ Asian Phytoceuticals Public Company LimitedAddress: 30th Floor, AIA Capital Center, 89 Ratchadaphisek Road, Dindaeng District, Bangkok 10400, ThailandPhone: 0-2646-4800Website: To view the source version of this press release, please visit Sign in to access your portfolio

Putin is set to take questions from international journalists

timean hour ago

Putin is set to take questions from international journalists

ST. PETERSBURG, Russia -- ST. PETERSBURG, Russia (AP) — Russian President Vladimir Putin is set to take questions Wednesday from international journalists on the sidelines of the St. Petersburg International Economic Forum. Putin scheduled a roundtable session with senior news leaders of international news agencies, including The Associated Press. Among other issues, he's expected to spell out Moscow's position on the conflict between Israel and Iran that he offered to help mediate in a weekend call with U.S. President Donald Trump. Russia has maintained a delicate balancing act in the Middle East for decades, trying to navigate its warm relations with Israel even as it has developed strong economic and military ties with Iran, a policy that potentially opens opportunities for Moscow to play power broker to help end the confrontation. Putin's comments will also be watched closely for clues to his strategy in the three-year conflict in Ukraine, where Russia has intensified its aerial campaign and stepped up ground attacks along the more than 1,000-kilometer (over 600-mile) front line. He has effectively rejected Trump's offer of an immediate 30-day ceasefire, making it conditional on a halt on Ukraine's mobilization effort and a freeze on Western arms supplies. The Russian leader has used the annual forum to highlight Russia's economic achievements and seek foreign investment. Western executives, who attended the event in the past, have avoided it after Putin sent troops into Ukraine in February 2022, leaving it to business leaders from Asia, Africa and Latin America. On the sidelines of the forum, Putin is set to have meetings with Indonesian President Prabowo Subianto and former Brazilian President Dilma Rousseff, who now heads the New Development Bank created by the BRICS alliance of Brazil, Russia, India, China and South Africa. He's also expected to confer with top officials from China, South Africa and Bahrain and the head of the OPEC group of oil-producing countries. On Friday, he is set to attend a panel discussion at the forum, a venue he has used to make policy statements.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store